Please assess the completion status of the following clinical trial:

Trial Title: Daptomycin in Pediatric Patients With Bacterial Meningitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 3 months and \< 16 years~* Bacterial meningitis~* Written parental (or appropriate legal representative) informed consent prior to study inclusion~Exclusion Criteria~* Gram-negative bacteria in the CSF~* Creatinine clearance \< 80ml/min/1.73m2~* Creatinine phosphokinase level \> 2x upper age related norm~* Known allergy or hypersensitivity to daptomycin~* Known clinical significant cardiovascular, pulmonary, renal, hepatic, gastrointestinal, endocrine, hematologic, autoimmune disease, or primary immunodeficiency~* Height and weight below 3rd or above 95th percentile~* History of, or current muscular disease~* Underlying neurological disease with disruption of blood brain barrier~* Epilepsy~* Muscular weakness, history of peripheral neuropathy, or Guillain-Barré syndrome

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): i.v. daptomycin given 24 hours after first ceftriaxone dose at age appropriate dosage

Based on this trial design, predict the completion outcome and termination type (if applicable).